Treatment of chronic hepatitis C in active drug users

New England Journal of Medicine

Volumn 345, Issue 3, 2001, Pages 215-217

  Davis, Gary L ^a   Rodrigue, James R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

COST BENEFIT ANALYSIS; DEPRESSION; DISEASE TRANSMISSION; DRUG ABUSE; DRUG INDUCED DISEASE; DRUG SAFETY; HEPATITIS C; HUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; ETHICS, MEDICAL; HEALTH POLICY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MEDICAL FUTILITY; PATIENT COMPLIANCE; PRACTICE GUIDELINES; RISK; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0035913229     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107193450312     Document Type: Review

References (36)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Projecting the future healthcare burden from hepatitis C in the United States
3. Estimating future hepatitis C morbidity, mortality, and costs in the United States
4. Rising incidence of hepatocellular carcinoma in the United States
5. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
7. Peginterferon alfa-2a in patients with chronic hepatitis C
8. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial
9. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection
10. Epidemiology of hepatitis C virus infection in a suburban Detroit community
11. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
12. Sharing of drug preparation equipment as a risk factor for hepatitis C
13. Hepatitis C virus in intravenous drug users
14. Hepatitis C disease among injection drug users: Knowledge, perceived risk, and willingness to receive treatment
15. Impact of alcohol on the histological and clinical progression of hepatitis C infection
16. Former addicts face barriers to treatment for HCV
17. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
18. EASL International Consensus Conference on Hepatitis C: Consensus statement
19. Management of viral hepatitis: Clinical and public health perspectives - A consensus statement
20. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C
21. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population
22. An evaluation of eligibility for therapy among veterans with hepatitis C
23. Hepatitis C virus and depression in drug users
24. Treatment of persons with dual diagnoses of substance use disorder and other psychological problems
25. Consequences of alcohol consumption on host defense
26. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection
27. Biological responses to administered interferon in alcoholics
28. Interferon therapy for chronic hepatitis C in habitual drinkers: Comparison with chronic hepatitis C in infrequent drinkers
29. The alcoholic patient with hepatitis C virus infection
30. Lack of protective immunity against reinfection with hepatitis C virus
31. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
32. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users
33. A 33-year follow-up of narcotics addicts
34. Addict death rates during a four-year posttreatment follow-up
35. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
36. Methadone maintenance and hepatitis C virus infection among injecting drug users